20
Participants
Start Date
September 1, 2024
Primary Completion Date
September 30, 2026
Study Completion Date
October 31, 2026
Daratumumab
Daratumumab is not being administered as part of the study. Patients will receive daratumumab as part of their clinical care, and blood and urine will be collected in order to measure biomarkers pre- and post-daratumumab administration
RECRUITING
Brigham and Women's Hospital, Boston
Collaborators (1)
Janssen Pharmaceuticals
INDUSTRY
Brigham and Women's Hospital
OTHER